The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age
Open accessAbstract
Alzheimer’s and Parkinson’s diseases are the two most common forms of neurodegenerative diseases. The exact etiology of these disorders is not well known; however, environmental, molecular, and genetic influences play a major role in the pathogenesis of these diseases. Using Alzheimer’s disease (AD) as the archetype, the pathological findings include the aggregation of Amyloid Beta (Aβ) peptides, mitochondrial dysfunction, synaptic degradation caused by inflammation, elevated reactive oxygen species (ROS), and cerebrovascular dysregulation. This review highlights the neuroinflammatory and neuroprotective role of epigallocatechin-3-gallate (EGCG): the medicinal component of green tea, a known nutraceutical that has shown promise in modulating AD progression due to its antioxidant, anti-inflammatory, and anti-aging abilities. This report also re-examines the current literature and provides innovative approaches for EGCG to be used as a preventive measure to alleviate AD and other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Uttara, B., Singh, A., Zamboni, P., & Mahajan, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602823 · Cited by 3,378 · cited 1×
“In all variations of ROS generation, molecular oxygen must be triggered, and the cellular system has evolved many metalloenzymes that facilitate ROS generation upon the interaction of redox metals with O2 utilizing various catalytic pathways [80].”
BackgroundThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“IL-6 has been shown to have a myriad of inflammatory regulative properties [71], but it can also stimulate acute phase proteins leading to enhanced vascular permeability, lymphocyte provocation, and antibody creation.”
BackgroundComprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869 · cited 1×
“Due to the brain’s excessive metabolic rate and decreased capacity for cellular regeneration, it is highly susceptible to ROS [78].”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543 · cited 4×
“Aging and inflammation increase the generation of the ROS/RNS superoxide anion (O2•) that can react with NO to form peroxynitrite (ONOO-), which interferes with mitochondrial respiration and causes NO dyshomeostasis leading to mitochondrial dysfunction and neuronal death [88,89].”
BackgroundInfluentialRole of nitric oxide in inflammatory diseases
Sharma, J. N., Al-Omran, A., & Parvathy, S. S. (2007) · Inflammopharmacology · doi:10.1007/s10787-007-0013-x · Cited by 1,403
Microglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100
Brain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Role of oxidative stress in Alzheimer’s disease
HUANG, W.-J., ZHANG, X., & CHEN, W.-W. (2016) · Biomedical Reports · doi:10.3892/br.2016.630 · Cited by 1,023
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 1×
“Regarding AD, there have been no new FDA-approved drugs since 2003 and no authorized disease-modified treatment (DMT), although there have been many extensive clinical trials [32,33,128].”
BackgroundThe genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863
Gruver, A., Hudson, L., & Sempowski, G. (2007) · The Journal of Pathology · doi:10.1002/path.2104 · Cited by 834 · cited 1×
“Still, it can become detrimental when the immune response is prolonged (or chronic) due to immunosenescent aging, which leads to immune signaling dysregulation culminating in neurodegenerative pathogenesis [55,56].”
BackgroundOxidative stress in Alzheimer’s disease
Chen, Z., & Zhong, C. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1423-y · Cited by 797 · cited 3×
“Reactions of various ROS and reactive nitrogen species (RNS) with tyrosine lead to the production of 3-nitrotyrosine and dityrosine [79].”
BackgroundInfluentialCurrent and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 1×
“Regarding AD, there have been no new FDA-approved drugs since 2003 and no authorized disease-modified treatment (DMT), although there have been many extensive clinical trials [32,33,128].”
BackgroundMicroglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618 · cited 9×
“Furthermore, EGCG has been shown to halt th beta-secretase enzyme (BACE1), which is tasked with processing sAPP to Aβ [65].”
BackgroundInfluentialBateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · cited 1×
“Regarding AD, there have been no new FDA-approved drugs since 2003 and no authorized disease-modified treatment (DMT), although there have been many extensive clinical trials [32,33,128].”
BackgroundAnti-inflammatory Effects of Flavonoids in Neurodegenerative Disorders
Spagnuolo, C., Moccia, S., & Russo, G. L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.001 · Cited by 458
Prasanth, M. I., Sivamaruthi, B. S., Chaiyasut, C., & Tencomnao, T. (2019) · Nutrients · doi:10.3390/nu11020474 · Cited by 457
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
Estrogens, Neuroinflammation, and Neurodegeneration
Villa, A., Vegeto, E., Poletti, A., & Maggi, A. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1007 · Cited by 423 · cited 1×
“Androgens (testosterone) and estrogens may serve to prevent and treat neurodegenerative diseases due to their many anti-inflammatory properties, such as halting proinflammatory cytokine production, protection from oxidative stress, and modulation of Aβ production [120,121].”
BackgroundGlial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409
Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway
Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00629 · Cited by 401 · cited 1×
“The PI3K-AKT-mTOR signaling pathway is linked to insulin regulation (particularly cerebral insulin), reduced in aging individuals making them more susceptible to AD [105,106].”
BackgroundThe role of androgens and estrogens on healthy aging and longevity
Horstman, A. M., Dillon, E. L., Urban, R. J., & Sheffield-Moore, M. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls068 · Cited by 396 · cited 1×
“Aging is liable to cause a loss of sex hormones (androgens and estrogens), which induce muscle loss, muscle weakness, diminished functional performance, and reduced life span [124,125].”
BackgroundDoens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348 · cited 1×
“Protein recognition receptors (PPRs) sense pathogen recognition molecular patterns (PAMPs), whereas TLRs detect damage-associated molecular patterns (dAMPs) [59,60].”
BackgroundCholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
Sex differences in cognitive impairment in Alzheimer’s disease
Laws, K. R., Irvine, K., & Gale, T. M. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i1.54 · Cited by 307 · cited 1×
“Current studies show that sex differences exist in a cognitive decline concerning AD [117,118].”
BackgroundCholesterol in brain disease: Sometimes determinant and frequently implicated
Martín, M. G., Pfrieger, F., & Dotti, C. G. (2014) · The EMBO Reports · doi:10.15252/embr.201439225 · Cited by 304 · cited 1×
“A sequence of enzymatic reactions converts mevalonate into 3-isoprenyl pyrophosphate, farnesyl pyrophosphate, squalene, lanosterol, and via a 19-step process to cholesterol [214].”
BackgroundLipid and Lipoprotein Metabolism in Microglia
Loving, B. A., & Bruce, K. D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00393 · Cited by 255 · cited 1×
“Cytokine activation of microglia can be mediated by a high-fat diet [220].”
BackgroundMitochondrial and cellular mechanisms for managing lipid excess
Aon, M. A., Bhatt, N., & Cortassa, S. C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00282 · Cited by 253 · cited 1×
“Aging, unregulated food consumption, and reduced physical activity have led to a worldwide epidemic of obesity, insulin resistance, and metabolic conditions leading to diabetes, hyperlipidemia, and hypertension [206,207].”
BackgroundAnti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer’s Disease
Shal, B., Ding, W., Ali, H., Kim, Y. S., & Khan, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00548 · Cited by 234
Function of Green Tea Catechins in the Brain: Epigallocatechin Gallate and its Metabolites
Pervin, M., Unno, K., Takagaki, A., Isemura, M., & Nakamura, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153630 · Cited by 216
Lipid (per) oxidation in mitochondria: an emerging target in the ageing process?
Ademowo, O. S., Dias, H. K. I., Burton, D. G. A., & Griffiths, H. R. (2017) · Biogerontology · doi:10.1007/s10522-017-9710-z · Cited by 184 · cited 1×
“Aging, unregulated food consumption, and reduced physical activity have led to a worldwide epidemic of obesity, insulin resistance, and metabolic conditions leading to diabetes, hyperlipidemia, and hypertension [206,207].”
BackgroundProtective role of epigallocatechin-3-gallate in health and disease: A perspective
Chowdhury, A., Sarkar, J., Chakraborti, T., Pramanik, P. K., & Chakraborti, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.013 · Cited by 164 · cited 1×
“Tea is the second most frequently drank beverage in the world after water [133,134].”
BackgroundAlzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia
Eshraghi, M., Adlimoghaddam, A., Mahmoodzadeh, A., Sharifzad, F., Yasavoli-Sharahi, H., Lorzadeh, S., Albensi, B. C., & Ghavami, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073330 · Cited by 158
APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1
Tachibana, M., Holm, M.-L., Liu, C.-C., Shinohara, M., Aikawa, T., Oue, H., Yamazaki, Y., Martens, Y. A., Murray, M. E., Sullivan, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124853 · Cited by 156
Beneficial Effects of Flavonoids Against Parkinson's Disease
Jung, U. J., & Kim, S. R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4078 · Cited by 150 · cited 1×
“The symptoms of PD are resting tremor, rigidity, bradykinesia, gait difficulty, and postural instability; nonmotor symptoms include depression, anxiety, emotional changes, cognitive impairment, sleep difficulty, and olfactory dysfunction [9].”
BackgroundThe aging lysosome: An essential catalyst for late-onset neurodegenerative diseases
Nixon, R. A. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140443 · Cited by 149 · cited 1×
“Aging and inflammation act as precursors to autophagic dysregulation and bolster cell death by exacerbating the cellular burden misfolded and damaged cellular deposits and diminishing cellular degradative capacity cells and other modifications of intracellular proteolytic systems [95].”
BackgroundArber, C., Toombs, J., Lovejoy, C., Ryan, N. S., Paterson, R. W., Willumsen, N., Gkanatsiou, E., Portelius, E., Blennow, K., Heslegrave, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0410-8 · Cited by 148
Liver Dysfunction as a Novel Player in Alzheimer’s Progression: Looking Outside the Brain
Estrada, L. D., Ahumada, P., Cabrera, D., & Arab, J. P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00174 · Cited by 144
Microglia in Aging and Alzheimer’s Disease: A Comparative Species Review
Edler, M. K., Mhatre-Winters, I., & Richardson, J. R. (2021) · Cells · doi:10.3390/cells10051138 · Cited by 126
Alasmari, F., Alshammari, M. A., Alasmari, A. F., Alanazi, W. A., & Alhazzani, K. (2018) · BioMed Research International · doi:10.1155/2018/3087475 · Cited by 125
Bloomberg, M., Dugravot, A., Dumurgier, J., Kivimaki, M., Fayosse, A., Steptoe, A., Britton, A., Singh-Manoux, A., & Sabia, S. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30258-9 · Cited by 114 · cited 2×
“[119] evaluated cognitive decline and performance correlated to aging and education and found that women had stronger memory and lesser memory decline than men regardless of education level.”
BackgroundAn Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111 · cited 1×
“Aging alters the integrity of the brain and cognitive ability by intensifying the biomechanical force of the cerebral vasculature and changing vascular remodeling [184].”
BackgroundMicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
International, R., & Lines, L. (2014) · doi:10.3768/rtipress.2014.rr.0024.1412 · Cited by 89
Zhu, H.-Y., Hong, F.-F., & Yang, S.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094540 · Cited by 84 · cited 1×
“Recent research has displayed NO’s role in vascular dementia [85], in which similar inflammatory molecular mechanisms can be used in examining AD pathology.”
Background
Cited by
Oxidative stress in the eye and its role in the pathophysiology of ocular diseases
Böhm, E. W., Buonfiglio, F., Voigt, A. M., Bachmann, P., Safi, T., Pfeiffer, N., & Gericke, A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102967 · Cited by 301
Metadata
- Authors
- Payne, A., Nahashon, S., Taka, E., Adinew, G. M., & Soliman, K. F. A.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2022-02-25
- Volume
- 12
- Issue
- 3
- Pages
- 371
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W4214568954
- Cited by
- 165
- References
- 54
- FWCI
- 19.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.